Articles tagged with Blood Cancer
Researchers at the University of Southampton have identified a unique change in B cells that allows them to receive signals from molecules called lectins, enabling tumor growth. This discovery could pave the way for new treatments and early cancer detection methods.
A novel AI-powered blood test, DELFI, has been developed to detect lung cancer with high accuracy. The test uses machine learning to analyze cell-free DNA in the bloodstream and has been shown to identify over 90% of patients with lung cancer.
Researchers at Tel Aviv University successfully printed the first entirely active and viable glioblastoma tumor using a 3D printer. The 3D-bioprinted model includes functional blood vessels that simulate a real tumor, making it a promising tool for predicting treatment efficacy and drug development.
Fels and Fox Chase researchers found specific TET2 and DNMT3A mutations in leukemia patients that affect DNA repair pathways. These mutations make leukemia cells sensitive to PARP inhibitors, a type of targeted therapy, while others are resistant. The study aims to develop personalized therapies for patients with these mutations.
Scientists at University of California San Diego School of Medicine have developed a method to keep cultured hematopoietic stem cells healthy, positive news for patients seeking stem cell transplants. The findings also hint at a new way to ward off aging by super-activating the heat shock pathway.
Researchers at UVA Health System discovered that combining drug palbociclib with ruxolitinib could effectively treat myelofibrosis by preventing bone marrow scarring and improving blood cell counts. This potential new treatment offers a promising approach to devastating blood disorder.
A new study published in Blood Cancer Discovery reveals that children with acute myeloid leukemia (AML) who have more DNA changes in their blood stem cells are more likely to survive. The researchers hope that this finding can be used as a tool to identify high-risk patients and improve treatment outcomes.
A world-first study found that cancer patients receiving chemotherapy intravenously have more than double the risk of developing a blood clot or thrombosis if the vein is too small and the catheter occupies more than 45% of the vein. Researchers identified specific limits on catheter-to-vein ratios to reduce risks for cancer patients.
A new test with 'unprecedented early detection power' is being developed by a University of Houston researcher to detect cancer biomarkers in blood. The liquid biopsy method uses exosomes, small vesicles containing surface proteins and genetic materials, to improve the accuracy of measuring minimal residual disease (MRD) in cancer tumors.
Optical Genome Mapping (OGM) detects abnormalities in chromosomes extremely quickly and accurately, potentially replacing traditional techniques. This new technology has been proven effective in detecting hereditary disorders and could significantly improve patient care.
Two studies by CU Cancer Center researchers found that chronic inflammation can serve as a key factor in the development of leukemia. Chronic inflammation reduces the fitness of normal cells, hindering their ability to reproduce and creating space for cancer-causing mutations to proliferate. The findings support the theory of adaptive ...
A microfilter device capable of detecting trace amounts of cancer cells in one mL of blood has been developed by a Kumamoto University research group. The device uses dynamic deformation and nucleic acid aptamers to separate and capture CTCs, achieving a high detection capability and selective detection rate.
A blood test has been shown to be accurate enough for multi-cancer screening among people at higher risk of disease, detecting cancer signals from more than 50 types, and correctly identifying tumor locations. The test's sensitivity varies by type of cancer, with some cancers detected earlier than others.
A blood test detecting tiny amounts of circulating cancer DNA may identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery. The study found patients with a particular cancer DNA marker in their blood had a higher likelihood of cancer relapse, suggesting the potential for personalized treatment.
A large retrospective study found that convalescent plasma from recovered COVID-19 patients can improve the likelihood of survival among blood cancer patients hospitalized with the virus. The therapy, which involves transfusing plasma rich in antibodies, was associated with a lower death rate compared to those who did not receive it.
Researchers investigated the association between convalescent plasma treatment and mortality in hospitalized adults with hematologic cancers and COVID-19. The study found that convalescent plasma therapy was associated with improved survival rates among these patient groups.
Research shows that hospitalized individuals with active cancer are more likely to die from COVID-19 than those with a history of cancer or no cancer diagnosis. Patients with blood-related cancers face the greatest risk of death, while recent cancer therapy is not linked to worse outcomes.
A biomarker based on circulating tumour DNA (ctDNA) can predict the likelihood of bowel cancer recurrence after surgery and chemotherapy. The test measures ctDNA levels before and after treatment to provide real-time information on chemotherapy effectiveness.
Scientists found that platinum chemotherapy can cause genetic changes in children with neuroblastoma, leading to increased risk of secondary leukemia. The study's findings could lead to identifying high-risk children and tailoring their treatment plans to reduce this risk.
A new Penn Medicine study shows that blood cancer patients with lower antibody levels can rely on T cells to combat COVID-19. The research found that patients with higher CD8 T cell counts were more than three times likelier to survive than those with lower counts.
Researchers developed SaferSeqS to detect rare mutations in blood more efficiently and reduce sequencing errors. The technology has shown a marked improvement in sensitivity and specificity in detecting previously undetectable cancer-related mutations.
A new study has identified a genetic mutation in the CUX1 gene that contributes to the development of acute myeloid leukaemia. Targeting this pathway could lead to new targeted therapies for patients with poor-prognosis AML, which affects people of all ages and often requires intensive chemotherapy.
Researchers discovered a cancer-causing gene mutation that accelerates cerebral cavernous malformation growth, leading to seizures or stroke. Repurposing an anticancer drug showed promise in improving brain-vascular health and preventing bleeding into the brain tissue.
Researchers found that a specific gene called MPP8 suppresses the activity of 'jumping' genes, which can protect against certain blood cancers. This discovery may lead to new biomarkers and therapeutic targets for acute myeloid leukemia, the deadliest type of blood cancer.
A new study shows whole genome sequencing is at least as accurate and often better than conventional genetic tests for determining blood cancer treatment. The study found that sequencing identified additional genetic abnormalities in 17% of cases, changing the risk category for 19 patients.
Utah researchers identify mutation hotspots and find that approximately 2% of healthy participants had the same mutations as cancer patients. This study provides new insights into the development of blood cancers and may help identify people at risk.
A study by University of Birmingham scientists has shown that the balance of cells in blood is affected earlier than thought, particularly for families carrying mutant RUNX1 proteins. The research found that these mutations can change how genes respond and lead to different diseases.
Researchers at Indiana University School of Medicine have discovered a promising treatment approach for preventing acute graft-versus-host disease, a common complication of blood stem cell transplantation. The study found that using the oral drug sitagliptin reduces the risk of GVHD by inhibiting immune T cell activation.
A randomized clinical trial demonstrated the benefits of early integration of palliative care into oncology care for patients with high-risk AML. Patients who received integrated palliative and oncology care reported significantly better quality of life and lower levels of depression, anxiety, and PTSD.
The combination of venetoclax with chemotherapy improves outcomes for patients with AML and MDS, with a promising overall response rate and acceptable safety profile. Venetoclax also demonstrates efficacy in treating high-risk MDS when combined with azacitidine.
A recent study by Dana-Farber Cancer Institute scientists has found that clonal hematopoiesis can confer a health benefit in the setting of allogeneic stem cell or bone marrow transplants. Patients who received transplants from older donors with CH had a lower risk of relapse and longer survival compared to those without CH.
State crisis standards of care (CSC) guidelines in the US allocate scarce healthcare resources among cancer patients, requiring careful consideration of prioritization methods. The guidelines include provisions for blood products and palliative care, highlighting the need for nuanced decision-making in resource allocation.
The study demonstrated a paradigm shift in treating AML, proving that genetic information matching leads to better survival rates than traditional one-size-fits-all treatment. Patients who opted for precision medicine experienced lower early death rates and superior overall survival compared to those receiving standard of care.
Children transplanted for cancer are more likely to die from treatment-related complications if they live in poorer neighborhoods, research suggests. Having Medicaid versus private insurance was also associated with a higher chance of dying.
Researchers found that specific chemotherapy agents increase the likelihood of developing therapy-related acute myeloid leukemia or myelodysplastic syndrome. CH mutations are more frequent in genes protecting the genome from damage, such as TP53.
A clinical trial called REPAIR-MDS will test repurposed drugs to improve hematological responses in MDS, reducing or reversing life-limiting deficiencies in red blood cells. The trial aims to improve the outlook for people with this rare condition, which has limited treatment options.
Researchers identified a direct molecular link between meat and dairy diets and the development of cancer-associated antibodies in the blood, increasing cancer risk. The study found that consuming large amounts of red meat and cheese leads to high levels of these antibodies.
Researchers have developed a new diagnostic tool that can detect cancer cells in small blood samples and connect them to their original tumor. This method has shown significant correlations between circulating tumor cells and tumor expression levels, allowing for targeted therapeutic agents to be used more accurately.
Researchers at McMaster University have developed a prototype for a hand-held device that can read the levels of a cancer biomarker, similar to a blood-sugar monitor. The device simplifies cancer testing by allowing patients to collect samples at home and providing accurate results in minutes.
Researchers at Flinders University have discovered a blood serum microRNA biomarker signature for oropharyngeal squamous cell carcinoma, which may help detect other head and neck cancers. The signature has potential for surveillance, earlier diagnosis, and treatment of head and neck cancer.
A new liquid biopsy test has been developed to detect cancer by analyzing protein biomarkers from tumors in the blood. The study found that this approach showed a high sensitivity and specificity for detecting different types of cancer, including breast, colon, and lung cancers.
A new method of detecting circulating tumor cells (CTCs) has been developed using a powerful label-free detection method and machine learning algorithm. The technique achieved an overall accuracy of 88.6% in patient blood samples and 97% on cultured cells, outperforming existing methods.
A new study by University of Exeter researchers suggests that higher-end normal blood platelet counts may be indicative of an increased risk of cancer, particularly in older males. The research found a significant correlation between high platelet levels and the development of lung and colorectal cancers.
A non-invasive blood test, PanSeer, can detect five common types of cancers four years before conventional diagnosis methods. The test detected cancer in 91% of asymptomatic samples and accurately identified cancer-free samples 95% of the time.
New cost-effective technology enables advanced immunology studies on Tasmanian devils and reveals conserved immune pathways across 160 million years of evolution. The system can be applied to any vertebrate species, including humans.
A novel liquid biopsy method has been developed to detect early kidney cancer with high accuracy, including small and localized tumors that are often curable but difficult to detect. The test is nearly 100% accurate in blood samples but shows less accuracy in urine samples, which can be improved through technical optimization.
Dr. Ramachandran is exploring unique signatures from cell-free DNA to identify abnormal gene patterns associated with certain stages or types of cancers. His long-term goal is to use this knowledge to understand tumor processes without biopsies, identifying cancer biomarkers.
A good vitamin D status is associated with a lower cancer risk, particularly in colon and blood cancers. Vitamin D responsiveness varies between individuals, affecting their need for supplementation.
A research group from Kumamoto University found the transcription factor RUNX3 plays a cancer growth function in what was previously thought to be a tumor suppressor. RUNX3 is also linked to the initiation and propagation of MDS stem cells, making it a promising new therapeutic target.
Researchers at Washington State University have developed a technology that uses an electric field to concentrate and separate cancer biomarkers onto a paper strip, detecting miniscule levels of the markers in as little as 10 minutes. This breakthrough could lead to earlier detection of and faster treatments for cancer.
KinaRx LLC, a Purdue University-affiliated startup, has received a $2 million SBIR grant to develop novel kinase inhibitors for treating relapse in acute myeloid leukemia (AML) and other diseases. The company's platform aims to rapidly create complex drug molecules using bioinformatics and multi-component compound synthesis.
A recent study published in the British Journal of Haematology investigated COVID-19 infection outcomes in blood cancer patients, finding that most recovered despite weakened immune systems. Age and co-existing health conditions were significant factors in determining patient outcomes.
A study of over 12,000 patients found that those with abnormally small red blood cells had a higher risk of cancer. The research suggests that microcytosis could be an early indicator of various cancers.
A multicancer blood test safely detected 26 undiagnosed cancers and enabled potentially curative treatment in a study of over 9,900 women. The test was found to be complementary and additive to standard screening methods for detecting breast, colon, and lung tumors.
Researchers developed a multi-cancer blood test that detected some cancers, including ovarian cancers, and successfully screened for non-cancer causes before diagnostic tests. The test showed promise as a minimally invasive option to increase cancer detection rates in populations already following standard screening approaches.
A blood test developed by Thrive Earlier Detection Corp. has identified multiple cancers in over 10,000 women without a prior history of cancer. The study found that the test more than doubled the number of 'screen-detected' cancers, increasing from 25% to 52%.
A case study suggests that tocilizumab may effectively address severe COVID-19 symptoms in patients with multiple myeloma and other blood cancers. The patient's IL-6 levels decreased aftertocilizumab treatment, and his symptoms resolved.
The blood test uses methylation patterns to detect cancer and identify its origin, achieving a 93% accuracy rate. It can detect over 50 cancer types, including the most deadly ones, with a low false positive rate of 0.7%, often before symptoms show up.
A new blood test has been developed to detect a wide range of cancers, including breast, colorectal, and pancreatic cancer, with an accuracy rate of 99.3%. The test uses next-generation sequencing to analyze DNA methyl groups, which can indicate the presence of cancer.
The Caravaggio study found that oral apixaban is at least as effective as dalteparin in preventing recurrent venous thromboembolism and major bleeding events in patients with cancer. The trial showed no significant difference in the risk of major bleeding, including gastrointestinal cancers, between the two treatments.